During the Pharmtech trade fair in Moscow, Schott Pharmaceutical Packaging announced its plans to increase production capacities at its plant in Zavolzhe by more than 50%. Schott was the first international manufacturer in Russia to open a new GMP-compliant pharmaceutical packaging plant in the spring of 2011.
Schott Pharmaceutical Packaging continues to experience growth in Russia and now plans to increase production capacities at its plant in in Zavolzhe by more than 50%. The manufacturer announced this move at the Pharmtech trade fair in Moscow. “Expanding our presence in Russia represents an important strategic step for the benefit of our customers,” emphasizes Prof. Udo Ungeheuer, Chairman of the Board of Management of Schott AG. “We are seeing continued growth in demand for locally manufactured primary packaging that also meets all of the international standards for quality. This will result in shorter delivery routes and better export opportunities for our customers. In other words, by pursuing a consistent investment strategy, we will be helping our customers in the Russian pharmaceutical industry to achieve their own growth and quality objectives,” he adds.
The Russian pharmaceutical industry has experienced double-digit growth in recent years. State initiatives such as the government’s “Pharma 2020” strategy that seeks to encourage local manufacturing of high-quality medications according to the GMP standard (“Good Manufacturing Practice”) will continue this development. Schott became the first international manufacturer in Russia to open a new GMP-compliant pharmaceutical packaging plant in the spring of 2011. After all, the order situation has made it necessary to expand capacities earlier than expected. By setting up new production lines for vials and ampoules, Schott has now demonstrated consistency in taking the next step toward continuing to offer its Russian customers shorter delivery times.
“Thanks to our many years of experience and high international standards for quality, Schott is the right partner for the ambitious and growing Russian pharmaceutical industry,” Jürgen Sackhoff, Executive Vice President of the Pharmaceutical Systems division, adds. Here, he is referring to the growing quality requirements of the Russian pharmaceutical industry. “GMP will be required by law for all companies that manufacture in Russia starting in 2014 and Schott has the necessary know-how on helping its customers to establish GMP-certified manufacturing thanks to its 125 years of experience and global manufacturing network,” Ungeheuer concludes.
Schott Pharmaceutical Systems is one of the world’s leading suppliers of glass tubing and primary packaging for the pharmaceutical industry.
Schott is an international technology group with more than 125 years of experience in the areas of speciality glasses and materials and advanced technologies. The Schott Group maintains close proximity to its customers with manufacturing and sales units in all major markets. Its workforce of around 17,000 employees generated worldwide sales of approximately EUR 2.9 billion for the 2010/2011 fiscal year. Schott AG, with its headquarters in Mainz (Germany) is owned by the Carl Zeiss Foundation.